ZS Pharma

Committed to Advancing Patient Care

ZS-9

ZS-9 is an insoluble, non-absorbed zirconium silicate with a clearly defined three dimensional crystalline lattice structure that was designed and engineered to preferentially trap potassium ions. SPS (e.g., Kayexalate), the current standard of care for hyperkalemia in the United States, is a nonselective polymer resin. In contrast to nonselective polymer resins, the potassium selectivity of ZS-9 enables high in-vitro binding capacity for potassium ions even in the presence of other ions. Head-to-head in-vitro experiments demonstrate that ZS-9 has roughly ten times the potassium binding capacity of SPS. In our clinical studies, this selectivity has resulted in the following important differentiating characteristics for ZS-9 that we believe support its potential use to treat acute and chronic hyperkalemia:

• high efficacy, with 98% of patients from our completed clinical trials receiving a 10 gram dose returning to a normal level of potassium (between 3.5 and 5.0 mEq/L) in their blood, which is referred to as normokalemia, within 48 hours;

• rapid onset of action, with statistically significant reductions in potassium observed at one hour in patients receiving a 10 gram dose in our completed clinical trials;

• demonstrated ability in our studies to date to safely and effectively maintain normokalemia, with a low risk of reducing the level of potassium in the blood below 3.5 mEq/L, which is referred to as hypokalemia;

• potential suitability for chronic once daily administration;

• easily taken as a convenient oral suspension powder or dissolvable tablets;

• well-tolerated in our studies to date, with an incidence of adverse events similar to placebo;

• no effect on other electrolytes that are critical for normal physiological functioning, including sodium, calcium and magnesium; and

• stability at room temperature with a long shelf-life, which we expect will simplify distribution, physician sampling and storage for both physicians and patients.

Recent News

September 23, 2014

ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia

Download PDF

September 17, 2014

ZS Pharma to Present at the 21st Annual BioCentury NewsMakers Conference

Download PDF

September 15, 2014

ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

Download PDF
X

Keep up to date with the latest ZS Pharma News and Updates